Additional Locations, North Carolina Clinical Trials

A listing of Additional Locations, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 168 clinical trials
A Clinical Trial Investigating the Efficacy Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).

This is a multi-center, randomized, double blind, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo …

Asheville Neurology Specialists PA
 (6.4 away) Contact site
  • 07 Sep, 2021
  • +112 other locations
Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)

The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).

Bausch Site 210
 (4.0 away) Contact site
  • 28 Jan, 2021
  • +27 other locations
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

The optimal treatment for Stage I or Stage IIA non-small cell lung cancer (NSCLC) remains controversial. Radiographic surveillance alone has been recommended for stage I and stage IIA patients after the tumor is removed surgically from the lung, and this standard has been based on the fact that no previous …

squamous non-small cell lung cancer
adjuvant chemotherapy
lung carcinoma
kidney function test
non-squamous non-small cell lung cancer
Sarah Cannon- Messino Cancer Center
 (4.0 away) Contact site
  • 09 Jul, 2021
  • +31 other locations
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and …

Mission Hospital
 (5.9 away) Contact site
  • 05 Sep, 2021
  • +65 other locations
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and …

mild cognitive impairment
cognitive impairment
primary prevention
hmg-coa reductase inhibitor
Asheville Charles George VA Medical Center
 (6.9 away) Contact site
  • 26 Jun, 2021
  • +86 other locations
Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial)

The purpose of the study is to assess efficacy, safety and tolerability of treatment with zibotentan and dapagliflozin in combination and alone, compared with placebo in participants with chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73^2.

Research Site
 (6.2 away) Contact site
  • 15 Sep, 2021
  • +151 other locations
Atrasentan in Patients With Proteinuric Glomerular Diseases

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

type 2 diabetes mellitus
renal function
type 2 diabetes
ras inhibitor
Mountain Kidney and Hypertension Associates
 (6.2 away) Contact site
  • 12 Sep, 2021
  • +25 other locations
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by …

blast cells
Mission Hospital
 (5.9 away) Contact site
  • 01 Sep, 2021
  • +92 other locations
S1803 Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 …

induction therapy
AdventHealth Infusion Center Asheville
 (4.0 away) Contact site
  • 07 Mar, 2021
  • +550 other locations
Determination of the Optimal Treatment Target in Ulcerative Colitis

Disease activity and response to therapy in ulcerative colitis (UC) can be assessed by a range of endpoints including symptoms, endoscopic mucosal activity, histological disease activity, and biomarkers. This study aims to determine the optimal treatment target, which is a research priority for the management of UC both to inform …

tumor necrosis factor
Asheville Gastroenterology Associates, PA
 (6.2 away) Contact site
  • 03 Sep, 2021
  • +22 other locations